Hiroshi Kida Selected Research

Biomarkers (Surrogate Marker)

1/2023	The elucidation of plasma lipidome profiles during severe influenza in a mouse model.
11/2022	Next-generation proteomics of serum extracellular vesicles combined with single-cell RNA sequencing identifies MACROH2A1 associated with refractory COVID-19.
1/2022	Long-Term Prognosis and Antimycobacterial Glycolipid Antibody as Biomarker in Mycobacterium avium-intracellulare Complex Pulmonary Disease.
12/2021	Advances and Challenges of Antibody Therapeutics for Severe Bronchial Asthma.
10/2021	Serum GPL core antibody levels are associated with disease activity and treatment outcomes in Mycobacterium avium complex lung disease following first line antibiotic treatment.
1/2021	Proteomics of serum extracellular vesicles identifies a novel COPD biomarker, fibulin-3 from elastic fibres.
10/2020	Oscillometry and computed tomography findings in patients with idiopathic pulmonary fibrosis.
12/2018	Semaphorin 7A promotes EGFR-TKI resistance in EGFR mutant lung adenocarcinoma cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hiroshi Kida Research Topics

Disease

60	Infections 02/2024 - 07/2002
46	Human Influenza (Influenza) 01/2024 - 08/2002
46	Influenza in Birds (Avian Flu) 01/2022 - 08/2002
17	Virus Diseases (Viral Diseases) 02/2024 - 01/2008
17	Neoplasms (Cancer) 10/2022 - 10/2010
12	Lung Diseases (Lung Disease) 04/2024 - 01/2013
12	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2022 - 08/2011
10	Chronic Obstructive Pulmonary Disease (COPD) 09/2023 - 03/2006
10	Inflammation (Inflammations) 10/2021 - 05/2011
8	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 09/2018 - 10/2010
7	Pneumonia (Pneumonitis) 01/2024 - 05/2009
7	Idiopathic Interstitial Pneumonias 01/2022 - 10/2014
7	Fibrosis (Cirrhosis) 10/2020 - 07/2002
6	Lung Neoplasms (Lung Cancer) 07/2022 - 01/2013
5	Idiopathic Pulmonary Fibrosis 01/2022 - 02/2004
5	Disease Progression 01/2021 - 10/2010
5	Neoplasm Metastasis (Metastasis) 02/2017 - 10/2010
5	Diarrhea 05/2015 - 02/2008
4	Asthma (Bronchial Asthma) 04/2024 - 03/2006
4	COVID-19 01/2024 - 11/2022
4	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2023 - 10/2014
4	Pulmonary Alveolar Proteinosis 01/2021 - 11/2014
4	Respiratory Insufficiency (Respiratory Failure) 05/2020 - 11/2014
4	Adenocarcinoma of Lung 11/2019 - 01/2012
3	Fever (Fevers) 01/2023 - 01/2013
3	Emphysema 01/2021 - 05/2011
3	Classical Swine Fever (Swine Fever) 01/2020 - 08/2012
3	Pulmonary Fibrosis (Fibrosing Alveolitis) 11/2014 - 07/2002
2	Cough 04/2024 - 10/2008
2	Viral Pneumonia 01/2021 - 01/2017
2	Body Weight (Weight, Body) 01/2021 - 11/2010
2	Bronchiectasis 10/2020 - 06/2020
2	Thrombocytopenia (Thrombopenia) 07/2020 - 01/2013
2	Autoimmune Diseases (Autoimmune Disease) 02/2020 - 01/2017
2	Sarcoidosis (Schaumann Disease) 02/2020 - 01/2017
2	Lung Injury 01/2020 - 01/2015

Drug/Important Bio-Agent (IBA)

44	VaccinesIBA 02/2024 - 08/2002
16	Proteins (Proteins, Gene)FDA Link 11/2022 - 11/2006
14	Hemagglutinins (Hemagglutinin)IBA 11/2021 - 08/2002
13	Neuraminidase (Sialidase)IBA 05/2022 - 07/2003
12	Antiviral Agents (Antivirals)IBA 01/2022 - 04/2002
9	AntigensIBA 02/2024 - 01/2005
9	AntibodiesIBA 02/2024 - 08/2002
9	Influenza Vaccines (Influenza Vaccine)FDA Link 01/2024 - 09/2008
9	CytokinesIBA 01/2024 - 07/2002
8	Biomarkers (Surrogate Marker)IBA 01/2023 - 12/2018
6	TetraspaninsIBA 01/2018 - 05/2009
5	baloxavirIBA 01/2024 - 01/2019
5	Oseltamivir (Tamiflu)FDA Link 01/2022 - 11/2011
5	Ether (Diethyl Ether)IBA 01/2022 - 06/2008
5	AutoantibodiesIBA 01/2022 - 11/2014
5	ChemokinesIBA 01/2021 - 06/2012
5	peramivirIBA 03/2017 - 11/2010
5	Monoclonal AntibodiesIBA 01/2017 - 01/2006
5	Amino Acids FDA Link 02/2016 - 12/2004
4	Neutralizing AntibodiesIBA 02/2024 - 08/2009
4	EndonucleasesIBA 01/2024 - 12/2018
4	Interleukin-6 (Interleukin 6)IBA 01/2024 - 05/2003
4	Clostridium perfringens epsilon-toxinIBA 02/2022 - 01/2020
4	Oxygen (Dioxygen)IBA 02/2022 - 10/2014
4	Formaldehyde (Formol)FDA Link 01/2022 - 07/2003
4	Immunoglobulin A (IgA)IBA 01/2022 - 01/2015
4	ThrombomodulinIBA 01/2021 - 01/2013
4	Viral RNAIBA 01/2021 - 03/2006
4	Interferon Type IIBA 01/2016 - 10/2010
3	AcidsIBA 01/2024 - 06/2020
3	Messenger RNA (mRNA)IBA 01/2024 - 04/2002
3	EnzymesIBA 01/2024 - 02/2004
3	C-Reactive ProteinIBA 01/2023 - 02/2004
3	Immunoglobulin E (IgE)IBA 11/2021 - 07/2005
3	Peptides (Polypeptides)IBA 11/2021 - 01/2012
3	Pancreatic Elastase (Elastase)IBA 01/2021 - 05/2011
3	Polysaccharides (Glycans)IBA 04/2020 - 02/2013
3	N-Acetylneuraminic Acid (Sialic Acid)IBA 04/2020 - 11/2010
3	Bleomycin (Blenoxane)FDA LinkGeneric 01/2020 - 07/2002
3	ErbB Receptors (EGF Receptor)IBA 02/2017 - 07/2012
3	Irinotecan (Camptosar)FDA LinkGeneric 01/2017 - 04/2012
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 11/2013 - 04/2012
3	Viral AntigensIBA 01/2006 - 11/2003
2	SolutionsIBA 01/2024 - 01/2006
2	AlbuminsIBA 01/2024 - 01/2020
2	GoldIBA 09/2023 - 01/2021
2	Phosphates (Orthophosphate)IBA 07/2022 - 01/2022
2	Viral Envelope ProteinsIBA 11/2021 - 07/2003
2	Zanamivir (Relenza)FDA Link 11/2021 - 01/2021
2	Bevacizumab (Avastin)FDA Link 07/2021 - 01/2013
2	Oncogene Proteins (Oncogene Protein)IBA 01/2021 - 08/2011
2	Acetaminophen (Paracetamol)FDA LinkGeneric 01/2021 - 11/2014
2	Interferon-alpha (Interferon Alfa)IBA 01/2021 - 01/2020
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021 - 03/2010
2	Detergents (Detergent)IBA 01/2021 - 01/2019
2	Interleukin-13IBA 01/2021 - 01/2017
2	Surface-Active Agents (Surfactants)IBA 01/2021 - 02/2004
2	Insulin (Novolin)FDA Link 01/2020 - 02/2004
2	Immunosuppressive Agents (Immunosuppressants)IBA 01/2020 - 01/2019
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2020 - 01/2019
2	pembrolizumabIBA 11/2019 - 01/2019

Therapy/Procedure

25	Therapeutics 04/2024 - 02/2002
8	Drug Therapy (Chemotherapy) 01/2022 - 02/2002
2	Immunotherapy 07/2022 - 01/2018